Press Releases<< Back
AlloSure data will be presented at ASN
In the beginning of October CareDx launched AlloSure following completion of the MolDX Technical Assessment process and subsequent Medicare coverage. AlloSure marks a new path in the surveillance of Kidney Transplant patients by directly monitoring the health of the organ through the measurement of donor-derived cell-free DNA.
Suphamai Bunnapradist, MD at
"In addition to the published data describing the use of AlloSure by itself to identify rejection, the data we are presenting at ASN highlights the potential to use AlloSure with DSA to identify antibody mediated rejection specifically," said
For more information, please visit: www.CareDx.com.
Forward Looking Statements
This press release contains forward-looking statements about our business, research, development and commercialization efforts, including statements regarding the potential to use AlloSure with DSA to identify antibody mediated rejection specifically. These forward-looking statements are based upon information that is currently available to us and our current expectations, speak only as of the date hereof, and are subject to numerous risks and uncertainties, including risks associated with successful research, development and planned commercialization of our technologies, that are described in our filings with the
Chief Commercial Officer
News Provided by Acquire Media